How to Vet an Emerging Fund Manager's Track Record Before Committing Capital

TL;DR: Before you commit a dollar to an emerging fund manager, verify that the track record they're pitching is actually theirs, read the IRR and multiples net of fees, call at least three prior LPs directly, and run the manager through SEC and FINRA background databases. In September 2024, the SEC charged a fund principal for using a fabricated "Performance Audit" to back up a trading track record that belonged to someone else entirely. The fund had already raised more than $16 million before regulators caught it. Track record fraud is not a tail risk in emerging manager investing. It is a documented, recurring pattern, and the burden of catching it falls on you, not the regulator.

I've sat across the table from dozens of first-time general partners (GPs, the people who manage the fund and make investment decisions) raising their debut vehicle, and the pitch always starts the same way: a track record slide showing gross IRR in the 30s, a marquee logo or two, and a claim that "I led this deal." Your job as the limited partner (LP, the investor who commits capital but doesn't make day-to-day decisions) is to figure out how much of that slide is true, how much is inherited credit from a prior employer, and how much is simply unverifiable. The Institutional Limited Partners Association (ILPA), the trade group that sets the de facto due diligence standard for private funds, built its Due Diligence Questionnaire specifically because LPs kept discovering gaps between what emerging managers claimed and what they could prove, according to ILPA's DDQ 2.0 documentation. If you skip this verification step because the deck looks polished and the GP is likeable, you are underwriting a story, not a track record.

Verify Attribution Before You Believe a Single Number

The single most common exaggeration in emerging manager pitches is not a fabricated deal. It is misattributed credit for a real one. A GP who was a junior associate on a deal at their prior firm will sometimes present it as "my deal" in a new fund's marketing materials. This is not always deliberate fraud. Sometimes it is sloppy self-promotion that nobody at the prior firm ever corrected. Either way, you need to establish exactly what role this person played on every deal in the track record before you give the numbers any weight.

Start by asking for a deal-by-deal attribution memo, not just a summary slide. For each investment claimed in the track record, you want:

• The GP's actual title and role at the time (sourcing, execution, portfolio management, or board oversight), not their current title applied retroactively
• Whether the GP was the deal lead, a member of an investment committee, or a supporting analyst
• The name of the fund or vehicle that actually held the investment, and whether that fund's LPs can confirm the GP's role
• Confirmation of whether the deal closed before or after the GP's employment dates at the prior firm, since attribution disputes over deals near a departure date are common

Then cross-reference independently. Search SEC EDGAR filings and Form ADV brochures for the prior firm to see whether the GP is named as a key person during the period in question. Search press releases, PitchBook, or Crunchbase for the deal itself and see who was credited publicly at the time, not in a bio written five years later. Ask the GP directly whether you may contact former colleagues to confirm role and tenure. A GP who resists, or who claims the prior firm is on bad terms, has handed you a red flag worth weighing heavily.

The Abraaj Group case is the extreme version of what happens when performance claims go unchecked at scale. The SEC charged the firm's former global head of fundraising, Mark Bourgeois, in 2022 for helping keep a private equity firm's true, weaker performance hidden from investors in a new $6 billion fund by delaying write-downs on struggling portfolio companies, according to the SEC's order against Bourgeois. Abraaj had once been one of the largest emerging-markets private equity firms in the world. Scale and reputation are not proxies for verified numbers.

Read IRR, MOIC, DPI, and TVPI the Way an Institutional LP Reads Them

Every performance metric in a fund pitch has a denominator, and the denominator is where GPs get creative. Know what sits on the bottom of each fraction before you trust the number on top.

Gross versus net is the first and most important split. Gross IRR (internal rate of return, the annualized return before fees and carried interest) excludes the roughly 2% annual management fee and 20% carried interest a typical fund charges. On a ten-year fund life, that fee drag alone can turn a 30% gross IRR into a net IRR in the low-to-mid 20s, and the gap widens for funds with high fee loads relative to a small asset base. If a GP's deck leads with gross IRR and the net figure is buried in a footnote, ask for it directly and get it in writing. A manager who hedges on this question in conversation is telling you something.

MOIC (multiple on invested capital) and TVPI (total value to paid-in capital) look similar but use different denominators. MOIC divides total value by capital actually deployed into deals, excluding fees. TVPI divides the same total value by paid-in capital, which includes fees. Because the TVPI denominator is larger, TVPI is almost always the lower, more conservative number, and a GP who quotes MOIC without disclosing it is quietly showing you the more flattering figure. Ask which denominator is used every time a multiple appears in a pitch.

Then there is the denominator effect itself, a term LPs use two ways. At the portfolio level, it describes what happened broadly across institutional LP portfolios in 2022 and 2023: public market values dropped sharply while private fund valuations lagged, so private allocations became an outsized share of total assets purely because the public-market denominator shrank, not because private performance improved. At the fund level, it means the same trick GPs use deal by deal: report early gains against a small base of invested capital to inflate an early multiple, before later capital calls dilute the denominator and the multiple normalizes. A fund showing a 4x MOIC eighteen months after first close, on only 15% of committed capital deployed, is almost always demonstrating a denominator effect from one early winner, not a repeatable strategy.

Insist on vintage-year context too. A fund that started deploying capital in 2010 operated in a completely different environment than one that started in 2021, with different interest rates, entry multiples, and exit windows. Ask the GP to benchmark their numbers against a named data source's quartile rankings for the same vintage year and strategy, not a vague claim of being "top quartile." If they cannot name Cambridge Associates, Preqin, or Burgiss and cite a specific percentile, treat the claim as unverified marketing language.

DPI (distributions to paid-in capital) is the number that cuts through all of this because a GP cannot mark it up. It measures actual cash returned to you, divided by capital called. A fund reporting a 2.5x TVPI and a 0.3x DPI in year eight has returned thirty cents on the dollar in real cash. The rest is a GP's opinion about what unsold companies are worth. The SEC's 2013 action against a former Oppenheimer private equity portfolio manager is instructive: by unilaterally revaluing the fund's largest holding from roughly $6 million to $9 million, and failing to disclose the new number was his own estimate rather than the underlying manager's, he pushed the fund's reported IRR for one quarter from 3.8% up to 38.3%, according to the SEC's press release on the case. The fund went on to raise tens of millions more from investors relying on the inflated figure. Unrealized marks are where inflation hides, and DPI is your defense against it.

Reference-Check the LPs, Not Just the References the GP Hands You

A reference list a GP prepares for you is not a diligence tool. It is a marketing document with phone numbers attached. Every name on it has already agreed to say something positive. Your job is to get past that list.

Ask the GP for the complete roster of LPs in their prior fund, not a curated subset, and request the fund administrator's contact information so you can independently verify capital account statements. Then ask your own network, placement agents, other family offices, RIA peers, whether anyone has a relationship with LPs from that fund who aren't on the GP's list. Unpicked references tend to give you the most useful information: whether capital calls were handled professionally, whether reporting was timely, and whether there were disputes over valuation or fees.

When you get an LP on the phone, ask direct questions. Did the manager hit their stated deployment pace? Were quarterly reports consistent with audited annual financials? Was there ever a valuation dispute, and how was it resolved? Would you commit to this manager's next fund at the same or a larger check size? A prior LP who won't re-up, or who answers vaguely instead of enthusiastically, is giving you a real signal even if they won't say anything overtly negative.

Regulatory background checks are non-negotiable and take less than twenty minutes. Run the GP and the management company through the SEC's Investment Adviser Public Disclosure database (IAPD, at adviserinfo.sec.gov), which shows registration status, the firm's Form ADV brochure, and any disciplinary disclosures for SEC- and state-registered advisers, according to Investor.gov's guide to using IAPD. Separately, check FINRA's BrokerCheck (brokercheck.finra.org) for any history as a registered broker, including customer disputes, terminations, or regulatory actions. IAPD and BrokerCheck cross-link, so run both. Then run a federal and state court docket search (PACER plus the relevant state systems) for civil litigation involving the GP, since neither database captures private suits that don't involve securities regulators. If a lawsuit from a former partner or a disgruntled LP turns up, raise it directly with the GP. How they explain it tells you as much as the lawsuit itself.

Red Flags That Should Stop Your Diligence Cold

Some warning signs are subtle. These are not. Treat any one of them as grounds to pause and dig deeper, and treat two or more together as grounds to pass.

• Deals that can't be independently confirmed. If a claimed deal doesn't appear in SEC filings, press coverage, PitchBook, or Crunchbase, and the GP can't produce a signed investment memo or capital account statement proving their involvement, don't count it.
• Gross-only reporting with no net figure offered voluntarily. A manager who only discloses net IRR when pressed, rather than upfront, is managing your perception, not informing your decision.
• TVPI or MOIC quoted with no DPI in sight. A fund narrative built entirely on unrealized marks is asking you to trust the GP's opinion of value rather than proof of cash.
• Marks that diverge from audited financials. Request the fund's audited financial statements from an independent administrator, not a GP-prepared summary, and reconcile the reported DPI against the actual cash flow statement. A mismatch is disqualifying, not a rounding error to wave off.
• Key-person concentration with no bench. If one person sourced, underwrote, and manages every deal in the track record with no documented investment committee or co-investment team, ask what happens to your capital if that person is unavailable for six months.
• Reluctance to let you contact the prior firm. A GP who is cagey about you verifying their history at a previous employer, citing vague bad terms, is asking you to take the track record on faith.
• Third-party audits or accolades you can't verify with the named auditor or publication directly. The Crawford Ventures case shows how far this can go: the fund's principals fabricated an entire "Performance Audit" attributed to a real Australian audit firm that had never done the work, and even created a fake email address to impersonate that firm, according to the SEC's September 2024 order. Call the named auditor yourself using contact information you find independently, never one provided by the GP.
• Reclassifying prior investments to flatter a specific track record. In an April 2020 case, the SEC fined a private fund manager $1 million after finding the firm had reclassified a strongly performing private fund investment as an early-stage direct drilling investment specifically to inflate the reported track record for that asset category, according to ACA Group's summary of the enforcement action. If a GP's track record categories seem to shift conveniently between pitches, ask why.

None of this diligence guarantees a good outcome. Plenty of honestly reported track records still underperform, because private markets are genuinely risky. What this process protects you against is a different, more preventable risk: committing capital to a story that was never true. Emerging managers deserve real consideration. Some of the best-performing funds in any vintage year come from first-time GPs nobody had heard of yet. But "emerging" is not a synonym for "unverifiable," and you have every tool you need, ILPA's framework, IAPD, BrokerCheck, court records, and a phone, to tell the difference before you sign a subscription agreement.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.